A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1
|
作者：
Giles, Francis
le Coutre, Philipp
Bhalla, Kapil
Rosti, Gianantonio
Ossenkopplele, G. J.
Alimena, Giuliana
Weitzman, Aaron
Rafferty, Teresa
Zheng, Ming
Kantarjian, Hagop
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Campus Virchow Klin, Berlin, Germany
[3] H Lee Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2170.2170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2170
引用
收藏
页码：615A / 616A
页数：2
相关论文
共 50 条
  • [21] Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib
    Giles, F. J.
    Larson, R. A.
    Kantarjian, H. M.
    le Coutre, P.
    Palandri, F.
    Haque, A.
    Gallagher, N.
    Ottmann, O. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study
    le Coutre, P.
    Giles, F. J.
    Apperley, J.
    Ottmann, O. G.
    Larson, R. A.
    Haque, A.
    Gallagher, N.
    Rosti, G.
    Cortes, J. E.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP)
    Jabbour, E.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K.
    Ossenkoppele, G. J.
    Hochhaus, A.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Expanding Nilotinib Access in Clinical Trials (ENACT) study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive (Ph plus ) chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP), or blast crisis (BC): Updated safety analysis
    Nicolini, F. E.
    Alimena, G.
    Al-Ali, H.
    Zaritskey, A. Y.
    Shen, Z.
    Jootar, S.
    Smith, G.
    Hsu, Y.
    Veronese, M. L.
    Rizzieri, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [26] Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
    Giles, Francis
    le Coutre, Philipp D.
    Bhalla, Kapil N.
    Ossenkoppele, Gert J.
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil J.
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [27] Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Baccarani, Michele
    de Coutre, Philipp D.
    Haque, Ariful
    Gallagher, Neil J.
    Cortes, Jorge
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1103 - 1103
  • [28] Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant philadelphia-positive (Ph plus) chronic myelogenous leukemia (CML) in either chronic phase (CP) or accelerated phase (AP)
    Jabbour, Elias
    Hochhaus, Andreas
    le Coutre, Philipp
    Baccarani, Michele
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Gattennann, Norbert
    Haque, Ari
    Gallagher, Neil
    Giles, Francis
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 315A - 315A
  • [29] DASATINIB LACK OF CROSS INTOLERANCE TO IMATINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (CML-CP) WHO ARE INTOLERANT TO IMATINIB - A RETROSPECTIVE SAFETY ANALYSIS
    Guilhot, E.
    Goldberg, S. L.
    Stone, R. M.
    Mauro, M.
    Matloub, Y.
    Chen, T. T.
    Khoury, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 51 - 51
  • [30] Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CMC) in chronic phase (CP) or accelerated phase (AP)
    Cortes, J.
    Jabbour, E.
    Hochhaus, A.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Hague, A.
    Gallagher, N.
    Giles, F.
    Hill, S.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 35 - 35
12345